AVS Bio acquires ImmunoPrecise Antibodies Europe unit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodi
August 6, 2025 8:00 AM EDTWASHINGTON & NORWICH, Conn.--(BUSINESS WIRE)-- Arlington Capital Partners (Arlington), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced that its portfolio company AVS Bio, a leading global provider of critical inputs and services for the bioprocessing and biologics industries, acquired ImmunoPrecise Antibodies (Europe) B.V. (IPA Europe or the Company). IPA Europe is a carve-out of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a biotherapeutics company leveraging proprietary technologies, including its LENSai platform, to accelerate the discovery of next-generation biologics. The acquisition expands AVS Bios European footprint and adds... More
